文献速递骨质疏松与代谢性骨病

FRAX系统筛查提高抗骨质疏松药物使用及依从性:英国SCOOP试验分析

Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial.
PubMed 文献 · Osteoporos Int · 2019-10-12

SCOOP试验纳入12,483名70-85岁女性,随机分为常规NHS护理组或FRAX工具(±DXA)评估组,高风险者推荐用药。筛查组6个月时用药者中38.2%在60个月时仍用药,对照组为21.6%;年龄增长与依从性差相关,父母髋部骨折史与依从性高相关。

要点

  • FRAX系统筛查使高危女性抗骨质疏松药物使用率及依从性高于常规护理。
  • 筛查组6个月用药者中38.2%在60个月仍用药,对照组为21.6%。
  • 年龄每增加1岁依从性降低(OR 0.96),父母髋部骨折史者依从性更高(OR 1.67)。

核心结论

  • 在骨折高风险女性中,使用FRAX系统筛查相比常规护理可提高抗骨质疏松药物的使用及依从性。

研究设计与样本

  • SCOOP为英国基层多中心随机对照试验,共12,483名70-85岁女性随机分入常规NHS护理组或FRAX±DXA评估组,高风险者推荐用药。
  • 通过邮寄问卷在6、12、24、36、48、60个月收集自我报告的AOM使用,分析限于随访期间开始用药者。

主要发现

  • 筛查组中高危且6个月时用药者,60个月时仍用药比例为38.2%;对照组相应比例为21.6%。
  • 年龄增长与依从性差相关(每增加1岁OR 0.96 [95%CI 0.93, 0.99],p=0.01)。
  • 父母髋部骨折史与依从性高相关(OR 1.67 [95%CI 1.23, 2.26],p<0.01)。

关键数值与推荐

  • 依从性良好定义为≥80%,差定义为<80%。
  • FRAX评估组高风险者推荐用药(原文未给出具体阈值或药物方案)。

临床怎么用

  • 原文结论:在骨折高风险女性中,FRAX系统筛查相比常规护理可提高AOM使用及依从性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In the large community-based SCOOP trial, systematic fracture risk screening using FRAX® led to greater use of AOM and greater adherence, in women at high fracture risk, compared with usual care. INTRODUCTION: In the SCreening of Older wOmen for Prevention of fracture (SCOOP) trial, we investigated the effect of the screening intervention on subsequent long-term self-reported adherence to anti-osteoporosis medications (AOM). METHODS: SCOOP was a primary care-based UK multicentre trial of screening for fracture risk. A total of 12,483 women (70-85 years) were randomised to either usual NHS care, or assessment using the FRAX® tool ± dual-energy X-ray absorptiometry (DXA), with medication recommended for those found to be at high risk of hip fracture. Self-reported AOM use was obtained by postal questionnaires at 6, 12, 24, 36, 48 and 60 months. Analysis was limited to those who initiated AOM during follow-up. Logistic regression was used to explore baseline determinants of adherence (good ≥ 80%; poor < 80%). RESULTS: The mean (SD) age of participants was 75.6 (4.2) years, with 6233 randomised to screening and 6250 to the control group. Of those participants identified at high fracture risk in the screening group, 38.2% of those on treatment at 6 months were still treated at 60 months, whereas the corresponding figure for the control group was 21.6%. Older age was associated with poorer adherence (OR per year increase in age 0.96 [95% CI 0.93, 0.99], p = 0.01), whereas history of parental hip fracture was associated with greater rate adherence (OR 1.67 [95% CI 1.23, 2.26], p < 0.01). CONCLUSIONS: Systematic fracture risk screening using FRAX® leads to greater use of AOM and greater adherence, in women at high fracture risk, compared with usual care.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Parsons CM, Harvey N, Shepstone L, et al. Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporos Int. 2019. PMID: 31606826. doi:10.1007/s00198-019-05142-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。